The global albumin market was valued at US$ 4.6 billion in 2020 and is projected to reach US$ 8.1 billion by the end of 2031, expanding at a compound annual growth rate (CAGR) of 6.1% from 2021 to 2031. Increasing demand for plasma-derived therapies, rising investments in life sciences, and the growing use of albumin in pharmaceutical manufacturing are expected to support market expansion.

Albumin is an essential blood protein that helps maintain osmotic pressure and supports the transportation of various substances throughout the body. Its ability to stabilize proteins, prevent aggregation, and act as a carrier for therapeutic compounds has made it an important component in pharmaceutical formulations, vaccines, drug delivery systems, and cell culture media.

Rising Prevalence of Chronic Diseases Supports Market Growth

The growing prevalence of liver diseases, kidney disorders, cardiovascular conditions, and severe infections is increasing the need for albumin-based therapies. These conditions can contribute to hypoalbuminemia, a condition characterized by low albumin levels in the blood. As healthcare providers focus on managing critical illnesses and improving patient outcomes, demand for human serum albumin products is expected to remain significant.

Human serum albumin is anticipated to account for approximately 80% of the global market revenue during the forecast period. Its established clinical applications, widespread adoption, and use in non-therapeutic applications contribute to the segment's leading position.

Recombinant Albumin Creates New Growth Opportunities

The shift toward recombinant albumin is emerging as a major trend in the market. Unlike plasma-derived products, recombinant albumin can help reduce reliance on human plasma supplies and minimize concerns related to serum-derived disease agents. It also offers advantages such as improved batch-to-batch consistency and greater control over product quality.

Technological advancements in recombinant production are creating opportunities for manufacturers to develop high-purity albumin for biopharmaceutical applications. However, complex production processes, high refinement costs, and stringent regulatory requirements remain important challenges for industry participants.

Expanding Applications in Drug Delivery and Vaccine Manufacturing

Drug delivery is expected to remain an attractive application segment as pharmaceutical and biotechnology companies explore albumin-based technologies. Albumin can function as a carrier in albumin fusion proteins, drug nanoparticles, and pro-drug formulations. These systems are being investigated for applications across several therapeutic areas, including cancer, diabetes, rheumatoid arthritis, and hepatitis.

Albumin is also gaining attention in vaccine manufacturing and cell culture media. Chemically defined, blood-free media containing albumin can support cell expansion and the production of biologics. Growing research into advanced vaccines and difficult-to-express viral products is expected to create additional commercial opportunities.

North America and Europe Offer Strong Market Potential

North America and Europe are projected to remain attractive regional markets due to substantial investments in life sciences, established biopharmaceutical industries, and research infrastructure. Government funding and ongoing product development activities are expected to support demand.

Meanwhile, India, China, Brazil, and South Africa offer emerging opportunities. Increasing healthcare investments, expanding contract research and manufacturing activities, and greater awareness of plasma protein therapies could support market penetration in these economies.

Competitive Landscape and Market Outlook

Key companies operating in the global albumin market include Albumedix A/S, CSL Behring LLC, Biotest AG, Grifols International S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, InVitria, HiMedia Laboratories Pvt. Ltd., SeraCare Life Sciences, and Sigma-Aldrich Co. (Merck KGaA).

Market participants are focusing on product innovation, regulatory approvals, strategic collaborations, distribution agreements, and production expansion. For instance, Grifols introduced its ALBUTEIN FlexBag portfolio innovation in November 2021 to improve storage and infusion convenience.

Going forward, demand for albumin is expected to benefit from expanding biopharmaceutical research, advances in recombinant technologies, and increasing applications in drug delivery and vaccine production. Manufacturers investing in production efficiency, product quality, and emerging markets may be well positioned to capture future growth.